Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil

Clinical Chemistry

Volumn 45, Issue 3, 1999, Pages 419-422

  Schütz, Ekkehard ^a   Shipkova, Maria ^a   Armstrong, Victor W ^a   Wieland, Eberhard ^a   Oellerich, Michael ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; GLUCURONIDE; INOSINATE DEHYDROGENASE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG GLUCURONIDATION; DRUG IDENTIFICATION; ENZYME INHIBITION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER MICROSOME; RECIPIENT; TRANSPLANTATION;

EID: 0032915733     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/45.3.419     Document Type: Article

References (15)

1. 1. Lipsky JJ. Mycophenolate mofetil. Lancet 1996;348:1357-9.
2. 2. Sievers TM, Rossi SJ, Ghobrial RM, Arriola E, Nishimura P, Kawano M, Holt CD. Mycophenolate mofetil. Pharmacotherapy 1997;17:1178-97.
3. 3. Mojarrabi B, Mackenzie PI. The human UDP glucuronosyltransferase, UGT1A10, glucuronidates mycophenolic acid. Biochem Biophys Res Commun 1997;238:775-8.
4. 4. Franklin TJ, Jacobs V, Jones G, Ple P, Bruneau P. Glucuronidation associated with intrinsic resistance to mycophenolic acid in human colorectal carcinoma cells. Cancer Res 1996;56:984-7.
5. 5. Nowak I, Shaw LM. Effect of mycophenolic acid glucuronide on inosine monophosphate dehydrogenase activity. Ther Drug Monit 1997;19:358-60.
6. 6. Tsina I, Kaloostian M, Lee R, Tarnowski T, Wong B. High-performance liquid chromatographic method for the determination of mycophenolate mofetil in human plasma. J Chromatogr B Biomed Appl 1996;681:347-53.
7. 7. Shipkova M, Niedmann PD, Armstrong VW, Schütz E, Shaw LM, Oellerich M. Simultaneous determination of mycophenolic acid and its glucuronide in human plasma using a simple high-performance liquid chromatography procedure. Clin Chem 1998;44:1481-8.
8. 8. Schütz E, Shipkova M, Armstrong VW, Niedmann PD, Weber L, Tönshoff B. et al. Therapeutic drug monitoring of mycophenolic acid: comparison of HPLC and immunoassay reveals new MPA metabolites. Transplant Proc 1998;30:1185-7.
9. 9. Shipkova M, Schütz E, Armstrong VW, Niedmann PD, Wieland E, Oellerich M. Overestimation of mycophenolic acid by EMIT correlates with MPA metabolite. Transplant Proc; in press.
10. 10. Shipkova M, Wieland E, Armstrong VW, Niedmann PD, Schütz E, Brenner-Weiss G, et al. Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of patients treated with MMF. Br J Pharmacol; in press.
11. 11. Bullingham RES, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmocokinet 1998;34:429-53.
12. 12. Hager PW, Collart FR, Huberman E, Mitchell BS. Recombinant human inosine monophosphate dehydrogenase type I and type II proteins. Purification and characterization of inhibitor binding. Biochem Pharmacol 1995;49: 1323-9.
13. 13. Sintchak MD, Fleming MA, Futer O, Raybuck SA, Chambers SP, Caron PR, et al. Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell 1996;85: 921-30.
14. 14. Spahn-Langguth H, Benet LZ. Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? Drug Metab Rev 1992;24:5-48.
15. 15. Griesmacher A, Weigel G, Seebacher G, Müller MM. IMP-dehydrogenase inhibition in human lymphocytes and lymphoblasts by mycophenolic acid and mycophenolic acid glucuronide. Clin Chem 1997;43:2312-7.